Abstract
Small cell lung cancer (SCLC) is characterized by an aggressive behaviour, but limited-stage disease could be treated with curative intent. In order to improve prognosis in terms of local control and survival in this setting, several studies evaluated the benefit of a multimodality strategy including surgery, chemotherapy and radiotherapy. Recently Yang et al. confirmed the benefit of adjuvant chemotherapy alone or with cranial irradiation in a population-based cohort of patients with early-stage SCLC who underwent complete surgical resection. Results of this study are consistent with previous retrospective analysis or small prospective trials without adding anything to the current knowledge and clinical practice. In this perspective, we discuss the role and evidence supporting different locoregional approaches, in a two-hand debate, underlining the importance of a prospective randomized trial defining the best treatment strategy in limited SCLC.
| Original language | English |
|---|---|
| Pages (from-to) | S276-S281 |
| Journal | Translational Cancer Research |
| Volume | 5 |
| DOIs |
|
| Publication status | Published - 2016 |
Fingerprint
Keywords
- Chemotherapy
- Limited
- Radiotherapy
- Small cell lung cancer (SCLC)
- Surgery
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging
- Cancer Research
Cite this
Multimodality treatment in limited small cell lung cancer (L-SCLC) : Different perspectives about the optimal approach. / Polo, Valentina; Pasello, Giulia.
In: Translational Cancer Research, Vol. 5, 2016, p. S276-S281.Research output: Contribution to journal › Comment/debate
}
TY - JOUR
T1 - Multimodality treatment in limited small cell lung cancer (L-SCLC)
T2 - Different perspectives about the optimal approach
AU - Polo, Valentina
AU - Pasello, Giulia
PY - 2016
Y1 - 2016
N2 - Small cell lung cancer (SCLC) is characterized by an aggressive behaviour, but limited-stage disease could be treated with curative intent. In order to improve prognosis in terms of local control and survival in this setting, several studies evaluated the benefit of a multimodality strategy including surgery, chemotherapy and radiotherapy. Recently Yang et al. confirmed the benefit of adjuvant chemotherapy alone or with cranial irradiation in a population-based cohort of patients with early-stage SCLC who underwent complete surgical resection. Results of this study are consistent with previous retrospective analysis or small prospective trials without adding anything to the current knowledge and clinical practice. In this perspective, we discuss the role and evidence supporting different locoregional approaches, in a two-hand debate, underlining the importance of a prospective randomized trial defining the best treatment strategy in limited SCLC.
AB - Small cell lung cancer (SCLC) is characterized by an aggressive behaviour, but limited-stage disease could be treated with curative intent. In order to improve prognosis in terms of local control and survival in this setting, several studies evaluated the benefit of a multimodality strategy including surgery, chemotherapy and radiotherapy. Recently Yang et al. confirmed the benefit of adjuvant chemotherapy alone or with cranial irradiation in a population-based cohort of patients with early-stage SCLC who underwent complete surgical resection. Results of this study are consistent with previous retrospective analysis or small prospective trials without adding anything to the current knowledge and clinical practice. In this perspective, we discuss the role and evidence supporting different locoregional approaches, in a two-hand debate, underlining the importance of a prospective randomized trial defining the best treatment strategy in limited SCLC.
KW - Chemotherapy
KW - Limited
KW - Radiotherapy
KW - Small cell lung cancer (SCLC)
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=84991794203&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84991794203&partnerID=8YFLogxK
U2 - 10.21037/tcr.2016.07.44
DO - 10.21037/tcr.2016.07.44
M3 - Comment/debate
VL - 5
SP - S276-S281
JO - Translational Cancer Research
JF - Translational Cancer Research
SN - 2218-676X
ER -